Stockwatch

Date	Sym	Type	Headline
2026-02-13 16:15	UU:SRRK	News Release200	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-02-10 08:00	UU:SRRK	News Release200	Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
2026-01-16 16:15	UU:SRRK	News Release200	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-01-12 07:00	UU:SRRK	News Release200	Scholar Rock Highlights 2026 Strategic Priorities
2026-01-05 08:00	UU:SRRK	News Release200	Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-13 10:57	UU:SRRK	News Release200	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-18 08:00	UU:SRRK	News Release200	Scholar Rock to Present at Upcoming Investor Conferences
2025-11-14 07:00	UU:SRRK	News Release200	Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights
2025-11-12 16:15	UU:SRRK	News Release200	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-04 08:00	UU:SRRK	News Release200	Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference
2025-10-23 08:00	UU:SRRK	News Release200	Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025
2025-10-17 16:15	UU:SRRK	News Release200	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-09-23 07:00	UU:SRRK	News Release200	FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility
2025-09-12 16:15	UU:SRRK	News Release200	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-08-15 16:15	UU:SRRK	News Release200	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-08-14 08:00	UU:SRRK	News Release200	Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment
2025-08-06 07:00	UU:SRRK	News Release200	Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress
2025-07-21 08:00	UU:SRRK	News Release200	Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025
2025-07-18 16:15	UU:SRRK	News Release200	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-23 08:00	UU:SRRK	News Release200	Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial
2025-06-18 07:00	UU:SRRK	News Release200	Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
2025-06-13 16:15	UU:SRRK	News Release200	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-05 08:00	UU:SRRK	News Release200	Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
2025-06-02 08:00	UU:SRRK	News Release200	Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager
2025-05-28 08:00	UU:SRRK	News Release200	Scholar Rock to Present at the Jefferies Global Healthcare Conference
2025-05-16 16:15	UU:SRRK	News Release200	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-14 07:00	UU:SRRK	News Release200	Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress
2025-05-07 08:00	UU:SRRK	News Release200	Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025
2025-05-06 16:15	UU:SRRK	News Release200	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-04-28 06:50	UU:SRRK	News Release200	Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth
2025-04-18 16:15	UU:SRRK	News Release200	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-25 07:30	UU:SRRK	News Release200	FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy
2025-03-16 19:00	UU:SRRK	News Release200	Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
2025-03-14 16:15	UU:SRRK	News Release200	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-02-27 07:00	UU:SRRK	News Release200	Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress
2025-02-25 16:15	UU:SRRK	News Release200	Scholar Rock to Participate in Upcoming Investor Conferences
2025-02-21 08:00	UU:SRRK	News Release200	Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference